Skip to main content
Skip to content
Case File
sd-10-EFTA01450729Dept. of JusticeOther

EFTA Document EFTA01450729

William Blair & Company, LLC. Exhibit 1 ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value (dollars in thousands) Drug Peak Sales Stage of Development Estimated Launch Date Probability of Commercialization Percentage of Sales to Company Probability. Adjusted NPV Value per Share Percentage of Fair Value Iclusig-CML 9746.822 Marketed January 2013/ 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013 AP28113—ALK* NSCLC S280918 Phase Ifl I 1-12 2016 81% 100% $3

Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01450729
Pages
1
Persons
0
Integrity
Loading PDF viewer...

Summary

William Blair & Company, LLC. Exhibit 1 ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value (dollars in thousands) Drug Peak Sales Stage of Development Estimated Launch Date Probability of Commercialization Percentage of Sales to Company Probability. Adjusted NPV Value per Share Percentage of Fair Value Iclusig-CML 9746.822 Marketed January 2013/ 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013 AP28113—ALK* NSCLC S280918 Phase Ifl I 1-12 2016 81% 100% $3

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
William Blair & Company, LLC. Exhibit 1 ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value (dollars in thousands) Drug Peak Sales Stage of Development Estimated Launch Date Probability of Commercialization Percentage of Sales to Company Probability. Adjusted NPV Value per Share Percentage of Fair Value Iclusig-CML 9746.822 Marketed January 2013/ 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013 AP28113—ALK* NSCLC S280918 Phase Ifl I 1-12 2016 81% 100% $325,268 $1.74 14.7% Worldwide Subtotal $2,189,243 $11.59 98.2% Net Cash at Yearend 2014 $63,406 $0.34 2.9% Net Present Value of additional Gain (Loss)' ($22,727) ($0.12) (1.0%) Sum-of-Parts Fair Value $2,209,922 $11.81 100.0% - Includes costs nal *Golly reined to programs above Sources. Company reports and %ma'am Emir 8 Company. L L.C. estimates 5 I Y. Katherine Xu, Ph.D. CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0 106554 SDNY_GM_00252738 EFTA01450729

Related Documents (6)

Dept. of JusticeOtherUnknown

EFTA Document EFTA01297437

Gratitude America - Google Search Page 1 of 1 403/, GrablUde IntoCa ck Alf Nen fl eas %know Maca atre 8-1linaS TWA, ;mow 44 300.033.4,6Sn 4031 SKWast GratitudeAmerica www.orasiudeamenetwei HONORING OUR. HEROES 'tannin Ow goner dew Reba. Restore. Recreate Reruns DotterteAppty lot a Reheat GratitudoAmetrices wassmn to 10 pomride Retreats Leadership Reba. Reface. & Reesman Out *Vets dem* a supoorton Van mutts Item gratiluleamened org • GratitudeAmerica. Inc - Home j Facebook

23p
Dept. of JusticeAug 22, 2017

1 May 1 1255-May 6 237_Redacted.pdf

Kristen M. Simkins me: Sent Tn: Subject: Atladimem: LT. THOMAS E. ALLEN JR Thomas S. Allen. Jr. Sunday. May BIL EDIE 12:55 AM Allyson FL Dwell; Brenda McKin1e?c C. Kay Wandring: Caitlyn D. Neff: Daniel?le Minarch?lck: JeFFrey' T. Hite; Jon D. Fisher. Jonathan M. Mfl?n-der. Joseph 5. Kolenorluan Mendez: Kevin T. Jeirles; [any Lidgett Lee R. Shea??er: Lorinda L. Brown.- Matti-new T. Fishet: Melanie Gordan; Michael S. Woods Richard C. 5mm; Shephanie D. Calander?mtus Report SMDIE 20150501004

493p
Dept. of JusticeAug 22, 2017

11 MAY 25-MAY 27 901_Redacted.pdf

Kristen M. Simkins From: Irons, Janet Sent: Wednesday, May 25, 2016 11-29 AM To: Richard C. Smith Cc: Jeffrey T. We Subject: Meeting with Prison Society tomorrow Hello Warden Smith, I'm writing in preparation for our meeting with you and Director Hite tomorrow at 9:30 to talk about the Law Library. We have been in touch with Kim Kelmor, Assistant Director ofthe Law Library at Penn State, who has experience with prison libraries. She has helpfully provided us with some questions and guida

186p
Dept. of JusticeAug 22, 2017

15 July 7 2016 - July 17 2016 working progress_Redacted.pdf

Kristen M. Simkins From: Sent: To: Cc: Subject: Irons, Janet < Tuesday, July 12, 2016 10:47 AM Richard C. Smith     Hello Warden Smith,     mother is anxious to hear the results of your inquiry into her daughter's health.   I'd be grateful if you could  email or call me at your earliest convenience.  I'm free today after 2 p.m.  Alternatively, we could meet after the Prison  Board of Inspectors Meeting this coming Thursday.    Best wishes,    Janet Irons    1 Kristen M. Simkins From: Sent:

1196p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01465999

Equity Research Healthcare I Biotechnology ARIAD Pharmaceuticals, Inc. Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12 On Friday, December 20, Ariad announced that it has reached agreement with the FDA for immediate reauthorization of Iclusig marketing in the United States, with a narrower label and accompanying Risk Mitigation Strategy (REMS) and postmarketing requirements (PMRs) Ariad plans to resume shipping of Iclusig by midJanu

19p
OtherUnknown

Gratitude America - Google Search

DOJ EFTA Data Set 10 document EFTA01297437

23p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.